A recent case series study, researchers investigated potential ophthalmic complications associated with the use of the antidiabetic drugs, semaglutide and tirzepatide. The retrospective review included nine patients who developed vision-related complications while using these medications; specifically, cases of nonarteritic anterior ischemic optic neuropathy, bilateral papillitis, and paracentral acute middle maculopathy. The researchers suggested a potential association between rapid glycemic control induced by these medications and observed ophthalmic events. The American Academy of Ophthalmology recommended that patients who experience vision loss while taking semaglutide should stop the drug and contact their prescribing physician. The Academy also suggested that a postmarketing surveillance study might better inform physicians and patients about the safety of semaglutide.

Source: JAMA Ophthalmology